Comparison of the metabolomic profiles of irritable bowel syndrome patients with ulcerative colitis patients and healthy controls: new insights into pathophysiology and potential biomarkers.

Related Articles Comparison of the metabolomic profiles of irritable bowel syndrome patients with ulcerative colitis patients and healthy controls: new insights into pathophysiology and potential biomarkers. Aliment Pharmacol Ther. 2019 Jan 31;: Authors: Keshteli AH, Madsen KL, Mandal R, Boeckxstaens GE, Bercik P, De Palma G, Reed DE, Wishart D, Vanner S, Dieleman LA Abstract BACKGROUND: Evaluation of the metabolomic profile of patients with irritable bowel syndrome offers an opportunity to identify novel pathophysiological targets and biomarkers that could discriminate this disorder from related conditions. AIM: To identify potential urinary…

Read More

Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared to standard of care in patients with inflammatory bowel disease.

Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared to standard of care in patients with inflammatory bowel disease. J Crohns Colitis. 2019 Jan 21;: Authors: Papamichael K, Juncadella A, Wong D, Rakowsky S, Sattler LA, Campbell JP, Vaughn BP, Cheifetz AS Abstract Background & Aims: Therapeutic drug monitoring (TDM) has proven to be effective for optimizing anti-TNF therapy in inflammatory bowel disease (IBD). Nevertheless, the majority of data refer to infliximab and reactive testing or association studies. We aimed to compare the long-term outcome of…

Read More

Variation in Care in the Management of Children With Crohn’s Disease: Data From a Multicenter Inception Cohort Study.

Variation in Care in the Management of Children With Crohn’s Disease: Data From a Multicenter Inception Cohort Study. Inflamm Bowel Dis. 2019 Jan 02;: Authors: Krishnakumar C, Ballengee CR, Liu C, Kim MO, Baker SS, Baldassano RN, Cohen SA, Crandall WV, Denson LA, Dubinsky MC, Evans J, Gokhale R, Griffiths A, Guthery SL, Oliva-Hemker M, Heyman MB, Keljo D, Kellermayer R, Leleiko NS, Mack DR, Markowitz JF, Moulton DE, Noe JD, Otley AR, Patel AS, Pfefferkorn M, Rabizadeh S, Rosh JR, Snapper S, Walters TD, Ziring D, Mondal K, Kappelman…

Read More

Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring.

Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring. Aliment Pharmacol Ther. 2019 Jan;49(2):147-154 Authors: Lucidarme C, Petitcollin A, Brochard C, Siproudhis L, Dewitte M, Landemaine A, Bellissant E, Bouguen G Abstract BACKGROUND: There are limited data concerning infliximab drug monitoring during de-escalation of the treatment of inflammatory bowel disease (IBD). AIM: To define the rate and the predictors of relapse following infliximab de-escalation in IBD patients in remission. METHODS: All IBD patients at a single referral…

Read More

Management of paediatric patients with medically-refractory Crohn’s disease using Ustekinumab: A multi-centred cohort study.

Management of paediatric patients with medically-refractory Crohn’s disease using Ustekinumab: A multi-centred cohort study. J Crohns Colitis. 2018 Dec 12;: Authors: Chavannes M, Martinez-Vinson C, Hart L, Kaniki N, Chao CY, Lawrence S, Jacobson K, Hugot JP, Viala J, Deslandres C, Jantchou P, Seidman EG Abstract Background: Ustekinumab (UST) is effective in the treatment of adults with moderate to severe Crohn’s disease (CD). There is a paucity of data on its use in children. Aim: To evaluate the response to UST in children with moderate to severe CD. Methods: This…

Read More

Implementation of CT-P13 via a Managed Switch Programme in Crohn’s Disease: 12-Month Real-World Outcomes.

Related Articles Implementation of CT-P13 via a Managed Switch Programme in Crohn’s Disease: 12-Month Real-World Outcomes. Dig Dis Sci. 2018 Dec 07;: Authors: Plevris N, Jones GR, Jenkinson PW, Lyons M, Chuah CS, Merchant LM, Pattenden RJ, Watson EF, Ho GT, Noble CL, Din S, Shand AG, Arnott ID, Lees CW Abstract BACKGROUND: Switching from Remicade to CT-P13 allows for significant cost savings and has been shown to be non-inferior to continued therapy with Remicade for the treatment of Crohn’s disease. AIM: The aim of this work was to prospectively…

Read More

Modulation of faecal metagenome in Crohn’s disease: Role of microRNAs as biomarkers.

Related Articles Modulation of faecal metagenome in Crohn’s disease: Role of microRNAs as biomarkers. World J Gastroenterol. 2018 Dec 14;24(46):5223-5233 Authors: Rojas-Feria M, Romero-García T, Fernández Caballero-Rico JÁ, Pastor Ramírez H, Avilés-Recio M, Castro-Fernandez M, Chueca Porcuna N, Romero-Gόmez M, García F, Grande L, Del Campo JA Abstract BACKGROUND: The gut microbiota plays a key role in the maintenance of intestinal homeostasis and the development and activation of the host immune system. It has been shown that commensal bacterial species can regulate the expression of host genes. 16S rRNA gene…

Read More

American Gastroenterological Association Institute Guideline on the Management of Mild-Moderate Ulcerative Colitis.

Related Articles American Gastroenterological Association Institute Guideline on the Management of Mild-Moderate Ulcerative Colitis. Gastroenterology. 2018 Dec 18;: Authors: Ko CW, Singh S, Feuerstein JD, Falck-Ytter C, Falck-Ytter Y, Cross RK, American Gastroenterological Association Institute Clinical Guidelines Committee PMID: 30576644 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30576644?dopt=Abstract

Read More

American Gastroenterological Association Technical Review on the Management of Mild to Moderate Ulcerative Colitis.

Related Articles American Gastroenterological Association Technical Review on the Management of Mild to Moderate Ulcerative Colitis. Gastroenterology. 2018 Dec 18;: Authors: Singh S, Feuerstein JD, Binion DG, Tremaine WJ Abstract Most patients with ulcerative colitis (UC) have mild to moderate disease activity, with low risk of colectomy, and are managed by primary care physicians or gastroenterologists. Optimal management of these patients decreases the risk of relapse and proximal disease extension, and may prevent disease progression, complications and need for immunosuppressive therapy. With several medications (sulfasalazine, diazo-bonded 5-aminosalicylates [ASA], mesalamines, corticosteroids…

Read More
<< Go Back